Edwards' Q3 Earnings on the Horizon: What's in the Cards?
EW heads into Q3 with TAVR momentum, expanding mitral and tricuspid therapies and surgical heart growth. Can it beat earnings estimates?
Zacks
Edwards' Q3 Earnings on the Horizon: What's in the Cards?
EW heads into Q3 with TAVR momentum, expanding mitral and tricuspid therapies and surgical heart growth. Can it beat earnings estimates?
Zacks
More News
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Zacks
ProDex Q1 Earnings Preview: Can Strong Sales Momentum Sustain Growth?
PDEX heads into fiscal Q1 earnings with strong medical-device sales and margin momentum, but customer concentration, a shrinking backlog and acquisition risks loom.
Zacks
SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds?
SYK's Q3 earnings may reflect strong hospital equipment demand and cybersecurity recovery, but supply constraints, vascular disruptions and margin pressures remain.
Zacks
WST Q3 Earnings Preview: Will HVP Strength Offset Vantage Weakness?
WST's Q3 earnings may benefit from strong HVP demand, biologics and GLP-1 growth, but West Vantage weakness and the SmartDose divestiture could weigh on sales.
Zacks
GEHC Ahead of Q3 Earnings: Can Strong Demand Offset Macro Headwinds?
GEHC heads into Q3 earnings with strong imaging demand and a record backlog, but PCS weakness, inflation and supply challenges could weigh on margins.
Zacks
$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.24% on an annualized basis producing an average annual return of 14.27%. Currently, Edwards Lifesciences has a market capitalizationread more...
Benzinga
INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?
Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.
Zacks
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.
Zacks
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.